PBH - Prestige Consumer Healthcare Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PBH

PRESTIGE CONSUMER HEALTHCARE INC.

NYSE

$51.31

▲ UP 1.56% (0.79)

KEY STATISTICS

Market Cap$2.43 B

52w High$71.07

52w Low$42.62

Dividend Yield1.25%

FrequencySpecial

P/E11.61

Volume265.12K

Shares Out.47.37M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Ronald Lombardi

COMPENSATION 2026

Salary$1,002,632

Stock Awards$3,700,034

Incentive Plan Pay$1,012,000

All Other Comp.$48,467

Total$5,763,133

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 10, 2005

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

890

PRICE TARGET

Target High$93.00

Target Low$66.00

Target Median$86.00

Target Consensus$81.67

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.$329.15M

NOV

THU

PRICE

$51.31 ▲ UP 1.56% (+$0.79)

About Prestige Consumer Healthcare Inc.

https://www.prestigebrands.com ↗

Prestige Consumer Healthcare Inc. develops, markets, and sells OTC health and personal care products globally, including brands like Chloraseptic, Dramamine, and Monistat, through various retail and e-commerce channels.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT PRESTIGE CONSUMER HEALTHCARE INC. IS KNOWN FOR

TheraTears Dry & Tired Preservative Free Lubricant Eye Drops

Launched in February 2026, Prestige Consumer Healthcare's new eye drops offer hydrating relief for eye fatigue and dryness from screen use, reflecting the company's focus on innovative eye care solutions for modern consumers.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q2-2026	Q3-2026	Q4-2026	Q1-2027
Gastrointestinal	$64.2M	$69.45M ▲	$68.35M ▼	$62.2M ▼
Womens Health	$56.2M	$57.77M ▲	$57.05M ▼	$52.54M ▼
Eye and Ear Care	$34.18M	$38.6M ▲	$37.85M ▼	—
Dermatologicals	$35.7M	$29.64M ▼	$30.49M ▲	$33.2M ▲
Analgesics	$28.73M	$28.03M ▼	$28.24M ▲	—
Cough and Cold	$27.29M	$29.33M ▲	$26.29M ▼	—
Oral Care	$24.77M	$26.58M ▲	$28M ▲	$22.36M ▼
Other OTC	$3.06M	$4.04M ▲	$5.35M ▲	—